

Appendix 4E

BioTech Capital Limited

ABN 45 091 979 172

Preliminary Final Report for the Year Ended 30 June 2007

1 Reporting period: year ended 30 June 2007 (previous period: year ended 30 June 2006)

2 **Results for announcement to the Market:**

2.1 Revenue from continuing operations	\$630,418	
- percentage change from previous period:	5.64%	(previous revenue of \$596,761)
2.2 Profit/(Loss) from continuing operations, after tax attributable to members:	-\$759,063	
- percentage change from previous period:	-107.13%	(previous loss of \$366,475)
2.3 Net Profit/(Loss) from continuing operations, attributable to members:	-\$759,063	
- percentage change from previous period:	-107.13%	(previous loss of \$366,475)
2.4 Dividend:	It is not proposed to pay a dividend	
2.5 Dividend record date:	Not applicable	
2.6 Further explanation of the figures contained in 2.1 to 2.3 is contained in the attached Financial Report		

3 An income statement for the period, together with notes to the statement, prepared in accordance with AASB 101, is contained in the attached Financial Report.

4 A balance sheet at the balance date, together with notes to the statement, is contained in the attached Financial Report.

5 A cash flow statement for the period, together with notes to the statement, is contained in the attached Financial Report.

6 There are no dividends or distributions to be detailed.

7 There are no dividend or distribution reinvestment plans in operation.

8 A statement of retained earnings showing movements is contained in the attached Financial Report.

9 Net tangible assets per share Current and Previous period: **\$0.43** **\$0.52**

10 The company has neither gained nor lost control of any entities during the period.

11 The company has no associate or joint venture relationships with any entities.

12 All significant information needed to enable an investor to make an informed assessment of the company's financial performance is contained in this appendix and the attached Financial Report.

13 The company is an Australian company registered under the Pooled Development Funds Act, 1992.

Appendix 4E

cont.... Page 2/2

BioTech Capital Limited

Preliminary Final Report for the Year Ended 30 June 2007

- 14 A commentary on the results for the period is contained in the attached Financial Report, including:
- 14.1 earnings per share and the nature of any dilution aspects;
 - 14.2 returns to shareholders including any distributions and buy backs;
 - 14.3 significant features of operating performance (see below);
 - 14.4 results of any segments that are significant to an understanding of the business as a whole;
 - 14.5 discussion of any trends in performance;
 - 14.6 Any other factors which have affected results in the period, or are likely to affect results in the future.

- 15 The information contained in this appendix and the attached Financial Report are based on accounts which are in the process of being audited.

- 14.3 In August 2006, Lazard Asset Management notified an increase in its shareholding in the Company to 7.43%.

In December 2006, Select Asset Management notified an increase in its shareholding in the Company to 22.09%.

In January 2007, the Company announced an extension to its on market share buyback to 16 November 2007.

In March 2007, Stem Cell Sciences (SCS) announced it is raising up to \$12million through an issue of shares. In April the issue closed oversubscribed and SCS announced dual listing on the Australian Stock Exchange with its primary listing being on London's Alternative Investment Market.

In May 2007, the Company announced it had become the largest shareholder in Neurodiscovery Limited with an investment of \$0.8million, holding 4,700,000 ordinary shares.

In June 2007, the Company announced it was investing \$2million in hearing technology company Sensear Pty Ltd.